Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Pfizer Inc (PFE) Price & Performance

iShares MSCI United Kingdom (FTSE)Trade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI United Kingdom (FTSE) vs Pfizer Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.93, while Pfizer Inc trades at $25.11 (market cap $141.46B). The key difference: Pfizer Inc pays a 6.93% dividend while iShares MSCI United Kingdom (FTSE) pays none, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.

EWUPFE
Sector
Broad Market / FactorHealth
52-Week High
$48.68$28.56
52-Week Low
$39.80$23.29
Market Cap
$141.46B
Volume
29,869,932
Enterprise Value
$192.12B
Dividend Yield
6.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, trades at $46.88, up 1.23% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The fund provides exposure to UK equities, which are influenced by rising oil prices and Middle East tensions, as highlighted in recent financial news. A dividend of $0.67 is scheduled for payment on June 18, 2026.

The outlook for EWU is cautiously optimistic, supported by technical strength and sector gains in energy. However, risks include geopolitical volatility and potential economic slowdowns in the UK. Investors should weigh the ETF's diversification benefits against exposure to regional uncertainties and currency fluctuations.

Pfizer Inc

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE